161 related articles for article (PubMed ID: 37794102)
21. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
Aldana J; Gardner ML; Freitas MA
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
[TBL] [Abstract][Full Text] [Related]
22. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Basheer F; Giotopoulos G; Meduri E; Yun H; Mazan M; Sasca D; Gallipoli P; Marando L; Gozdecka M; Asby R; Sheppard O; Dudek M; Bullinger L; Döhner H; Dillon R; Freeman S; Ottmann O; Burnett A; Russell N; Papaemmanuil E; Hills R; Campbell P; Vassiliou GS; Huntly BJP
J Exp Med; 2019 Apr; 216(4):966-981. PubMed ID: 30890554
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Nikoloski G; Langemeijer SM; Kuiper RP; Knops R; Massop M; Tönnissen ER; van der Heijden A; Scheele TN; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2010 Aug; 42(8):665-7. PubMed ID: 20601954
[TBL] [Abstract][Full Text] [Related]
24. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
25. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
[TBL] [Abstract][Full Text] [Related]
26. [Construction of EZH2 Knockout Animal Model by CRISPR/Cas9 Technology].
Meng F; Zhao D; Zhou Q; Liu Z
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):358-364. PubMed ID: 29764585
[TBL] [Abstract][Full Text] [Related]
27. Aberrant Expression of
de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
[TBL] [Abstract][Full Text] [Related]
28. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones.
Saeed BR; Manta L; Raffel S; Pyl PT; Buss EC; Wang W; Eckstein V; Jauch A; Trumpp A; Huber W; Ho AD; Lutz C
Int J Cancer; 2021 Jun; 148(11):2825-2838. PubMed ID: 33411954
[TBL] [Abstract][Full Text] [Related]
29. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
31. Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.
Xie H; Peng C; Huang J; Li BE; Kim W; Smith EC; Fujiwara Y; Qi J; Cheloni G; Das PP; Nguyen M; Li S; Bradner JE; Orkin SH
Cancer Discov; 2016 Nov; 6(11):1237-1247. PubMed ID: 27630126
[TBL] [Abstract][Full Text] [Related]
32. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
33. Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia.
Yang X; Wan M; Yu F; Wu X
Cell Signal; 2021 Nov; 87():110144. PubMed ID: 34509612
[TBL] [Abstract][Full Text] [Related]
34. Mutational mechanisms of EZH2 inactivation in myeloid neoplasms.
Chase A; Score J; Lin F; Bryant C; Waghorn K; Yapp S; Carreno-Tarragona G; Aranaz P; Villasante A; Ernst T; Cross NCP
Leukemia; 2020 Dec; 34(12):3206-3214. PubMed ID: 32322039
[TBL] [Abstract][Full Text] [Related]
35. EZH2 mutation in an adolescent with Weaver syndrome developing acute myeloid leukemia and secondary hemophagocytic lymphohistiocytosis.
Usemann J; Ernst T; Schäfer V; Lehmberg K; Seeger K
Am J Med Genet A; 2016 May; 170A(5):1274-7. PubMed ID: 26762561
[TBL] [Abstract][Full Text] [Related]
36. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML; Athar M; Ferguson JE; Varambally S
Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
[TBL] [Abstract][Full Text] [Related]
37. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.
Tanaka S; Miyagi S; Sashida G; Chiba T; Yuan J; Mochizuki-Kashio M; Suzuki Y; Sugano S; Nakaseko C; Yokote K; Koseki H; Iwama A
Blood; 2012 Aug; 120(5):1107-17. PubMed ID: 22677129
[TBL] [Abstract][Full Text] [Related]
38. Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase.
Sbirkov Y; Kwok C; Bhamra A; Thompson AJ; Gil V; Zelent A; Petrie K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28678185
[TBL] [Abstract][Full Text] [Related]
39. Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
Romanchikova N; Trapencieris P
Anticancer Res; 2019 Aug; 39(8):4179-4184. PubMed ID: 31366503
[TBL] [Abstract][Full Text] [Related]
40. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
Wang JY; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]